What a tissue procurement agreement commits a hospital to

Tissue agreements sit in an unusual position in a health system's contract portfolio. Commercially they are modest, often a fraction of what the system spends on implantable devices. Operationally they carry some of the longest-lived and least forgiving obligations it holds, because the material is of human origin and the traceability requirements reflect that.

The obligations are well understood clinically. Surgical services and the tissue programme know that grafts must be logged, storage monitored and recalls actioned. What is frequently missing is the connection between that clinical practice and the agreements that impose it, so the accreditation status of a supplying bank is verified once at onboarding, the recall response window is nowhere on a calendar, and the retention period is whatever the general records policy says.

The consequence shows up in two situations: a recall notice arriving on a Friday afternoon, and an adverse reaction investigation asking which donor a graft came from. Both are answerable in minutes by an organization that holds implant records as queryable data linked to the supplying agreement. Both take days for an organization that does not, and the difference is entirely a matter of preparation.

The obligations that run in each direction

A tissue procurement agreement imposes duties on both parties, and the hospital's duties are the ones most likely to be untracked.

• Tissue bank warranties, donor eligibility and consent, processing and testing performed, accompanying documentation with each graft, and registration or accreditation maintained.
• Notification duties, recall or withdrawal notices, post-distribution findings affecting a released lot, and any change in the bank's regulatory or accreditation status.
• Hospital storage duties, specified temperature and handling conditions, continuous monitoring, excursion response and the records evidencing all three.
• Hospital traceability duties, a record linking each received graft to the patient implanted, queryable in both directions, retained for the full period.
• Hospital reporting duties, adverse reaction reports back to the bank within a stated window, recall action confirmations, and unused graft return or disposal records.

Each of these has a natural owner, but the owners sit in different functions: supply chain holds the agreement, the tissue programme holds the log, surgical services holds the implant record, and quality holds the excursion documentation. The obligations only work if those four can be reconciled on demand, which in most organizations requires deliberate design rather than existing by default. The reconciliation point is usually the graft identifier: where it is captured consistently at receipt and again at implant, both queries work, and where it is captured in one place but not the other, the chain has a break that no amount of process discipline elsewhere compensates for.

Controls that make the duties operable

Five controls address the failures reported most often when tissue obligations are managed clinically but not contractually.

• Hold accreditation as dated fields. Record each bank's registration and accreditation with expiry dates and advance notification, plus a standing duty on the bank to report any adverse change. Verification at onboarding alone leaves years uncovered.
• Link the implant record to the agreement. The graft identifier, donor identifier, lot, patient and supplying agreement should be retrievable together. Records held only in operative notes cannot support a recall query at speed.
• Put recall windows on the calendar. The response window, the confirmation duty and the escalation path belong in the obligation record with named owners, so a notice starts a defined sequence rather than a search for the contract.
• Keep excursion records against the graft. Storage monitoring data and excursion response should attach to the affected grafts, not only to the freezer. This is what supports a warranty claim and what a quality review will ask for.
• Reconcile received against used quarterly. Compare grafts received, implanted, returned and discarded. Unexplained gaps are the leading indicator that the traceability chain has a break in it, and quarterly is frequent enough to find the break while it is still explicable.

A five-step implementation path

Step 1, Inventory suppliers and agreements

List every tissue bank, distributor and procurement organization supplying the system, with its current agreement. Multi-site systems commonly find suppliers used at one hospital with no agreement on file centrally, which is the first thing to resolve.

Step 2, Abstract the obligation set

Capture recall windows, reporting duties, storage specifications, retention periods and accreditation requirements as fields. Where terms differ between suppliers, and they will, the variation itself is worth knowing.

Step 3, Establish the traceability query

Confirm that graft-to-patient and patient-to-graft queries can both be run, and time them. Where the record is incomplete, decide whether to remediate historical data or to fix the capture point going forward and document the cutover.

Step 4, Load the calendar and assign owners

Recall response, adverse reaction reporting, accreditation expiry and quarterly reconciliation each need a named owner and a cadence. Splitting ownership across functions is fine provided the obligations are visible in one register.

Step 5, Rehearse a recall

Run a tabletop exercise against a real lot, with the clock running. The exercise surfaces the handoff that breaks, which is almost always between the supply record and the clinical record, and it is far better found in rehearsal.

Where this sits alongside other supply obligations

Tissue agreements are one of several supply relationships in a health system that carry obligations beyond price and delivery: implantable device agreements with their own tracking duties, pharmacy arrangements with pedigree and storage requirements, and group purchasing commitments with tier and account-separation conditions. Running them through separate trackers produces inconsistent evidence conventions and duplicated review cycles. The contract-inventory discipline set out in provider contract management for health systems applies equally here, and the commitment-tracking approach in obligation management for healthcare gives these duties the same owners, calendars and evidence standards as the rest of the portfolio.

Obligations, windows and evidence

The table below maps the recurring duties to their triggers and the artifact each one has to produce.

Tissue obligations are demanding but finite, and the organizations that handle them well are not doing anything sophisticated. They hold the supplier's accreditation dates as fields, keep the implant record queryable in both directions, put the recall window on a calendar with an owner, and rehearse once a year. That combination turns a Friday afternoon recall notice into a routine morning's work rather than an incident. It also stands up considerably better in an accreditation survey, because the evidence for each duty exists as a record rather than as an account of what the organization would do if asked.

For related guidance, see The compliance guide to BAA tracking across vendors, The provider’s guide to GPO and 340B contract control and Value-based care contract administration, simplified.

Aavenir Healthcare PracticePractitioner guidance on provider agreements, compliance obligations and audit evidence from the Aavenir healthcare practice.